Sionna Therapeutics, Inc.

Sionna Therapeutics announced topline data from its PreciSION CF Phase 2a trial of SION-719 and its Phase 1 trial of SION-451 dual combinations. The SION-719 trial, evaluating it as an add-on to standard of care for cystic fibrosis, did not meet its key activity endpoint of sweat chloride reduction. Consequently, the company will not advance SION-719 as an add-on to standard of care and plans to preserve capital while evaluating next steps for its SION-451 program, which met safety and pharmacokinetic objectives in healthy subjects. The company ended Q2 with approximately $268.3 million in cash.

Sionna Therapeutics reported that its SION-719 Phase 2a proof-of-concept trial did not meet its key activity endpoint of sweat chloride reduction when added to standard of care. Consequently, the company will not advance SION-719 as an add-on therapy. Sionna is evaluating potential confounders from the SION-719 trial to inform next steps for its SION-451 dual combination clinical program, which showed positive Phase 1 safety and pharmacokinetic results. The company ended Q2 with approximately $268.3 million in cash and plans to preserve capital.

Sionna Therapeutics reported a net loss of $56.7 million for the six months ended June 30, 2026, compared to $34.6 million for the same period in 2025, driven by increased research and development and general and administrative expenses. The company's cash, cash equivalents, and marketable securities totaled $268.3 million as of June 30, 2026, which is expected to fund operations for over 12 months. Additionally, Sionna established an "at the market" equity offering program in March 2026 to sell up to $250.0 million in common stock, though no shares have been sold yet.

Sionna Therapeutics reported a net loss of $29.9 million for the second quarter ended June 30, 2026, an increase from $18.1 million in the same period last year, driven by higher R&D and G&A expenses. The company maintained a strong cash position with $268.3 million in cash and equivalents, projected to fund operations into 2028. Operationally, Sionna confirmed that its PreciSION CF Phase 2a trial for SION-719 and Phase 1 dual combination trial for SION-451 are both on track to deliver topline data this summer.

Sionna Therapeutics reported its second-quarter 2026 financial results and provided a business update, highlighting significant progress in its clinical pipeline. The company's PreciSION CF Phase 2a trial for SION-719 and the Phase 1 dual combination trial for SION-451 are both on track to deliver topline data in summer 2026. Financially, Sionna maintained a strong cash position with $268.3 million in cash and equivalents, projected to fund operations into 2028, despite an increased net loss of $29.9 million for the quarter due to higher R&D and G&A expenses.

Sionna Therapeutics, a clinical-stage biopharmaceutical company, announced that its management will participate in two upcoming investor events. These include a presentation at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, and a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. Live webcasts and replays will be accessible through the company's investor relations website.

Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis, announced that its management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference. The event is scheduled for May 20, 2026, at 2:05 p.m. ET. A live webcast and replay will be available on the company's investor relations website.

Sionna Therapeutics reported a net loss of $26.8 million for Q1 2026, an increase from $16.5 million in Q1 2025, driven by higher research and development and general and administrative expenses. The company established an at-the-market equity offering program to sell up to $250.0 million in common stock, though no shares have been sold yet. Despite the increased loss, the company believes its $289.9 million in cash, cash equivalents, and marketable securities will fund operations for over twelve months.

Sionna Therapeutics reported a net loss of $26.8 million for the first quarter of 2026, an increase from $16.5 million in the prior year, primarily due to higher research and development and general and administrative expenses. The company announced the completion of enrollment in its PreciSION CF Phase 2a trial for SION-719, with topline data expected in Summer 2026. Sionna also maintained a strong cash position of $289.9 million, which is projected to fund operations into 2028.

Sionna Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 17, 2026. Stockholders of record as of April 21, 2026, are entitled to vote on the election of four Class II directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The company is utilizing the "Notice and Access" rule for proxy materials.